Threat to HIV business spooks GlaxoSmithKline shares

LONDON (Reuters) - The threat of new competition and potential loss of market share in GlaxoSmithKline's flagship HIV drug business unnerved investors in Britain's biggest drugmaker on Wednesday, sending the shares 1.5 percent lower in early trade.